AI-generated summary
The authors report on the evidence for low-level laser therapy in preventing and treating oral mucositis in patients receiving chemotherapy or radiotherapy for head and neck cancer. They cite a meta-analysis of 11 placebo-controlled trials that found reduced oral mucositis risk, pain and duration at doses of 1 to 6 joules per point, and describe an ongoing French phase III trial. The authors suggest the approach could become a standard of care, though they note no consensus on procedure exists.
- Participants
- 415
- Studies included
- 11
- Who or what was studied
- Patients treated with chemotherapy and/or radiotherapy for head and neck cancer
- Limits stated in the abstract
- The abstract notes no consensus on the laser procedure and that the ongoing trial is still in progress, with a planned sample of about 100 patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on jstage.jst.go.jp.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Oral mucositis, Laser, Dose, Placebo-controlled, Meta-analysis, Wavelength, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.